Endocrinology, Vol 137, 5230-5235, Copyright © 1996 by Endocrine Society

ARTICLES

Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells

AC Dalkin, JT Gilrain, D Bradshaw and CE Myers
Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA. acd6v@virginia.edu

Prostate epithelial cell growth is under the control of both steroid and peptide factors. Human prostate cancer cell lines have been used to investigate similar agents in malignancy. Activins are dimeric peptides structurally related to transforming growth factor-beta and produced in the gonads and a wide array of extragonadal tissues. The activins act at the pituitary to regulate the synthesis and secretion of FSH. At other sites, such as bone marrow, liver, and gonads, activin may play an important role in the regulation of cell growth and differentiation. It was the purpose of the current study to determine whether activin had similar actions on prostate cancer cells, specifically the androgen- responsive LNCaP and the androgen-resistant PC-3 cell lines. Using reverse transcription-PCR, messenger RNAs for type I and type II activin receptor subunits as well as the activin-binding protein follistatin were detected in both cell lines. Activin treatment rapidly (<24 h) inhibited LNCaP, but not PC-3, cell growth. The effects of activin were evident at low levels, with a concentration of 5 ng/ml being effective at 24 h, and a concentration of 0.5 ng/ml being effective at 48 h. These results contrasted with the actions of transforming growth factor-beta, which inhibited only PC-3 cells and required a greater treatment duration (96 h) to be effective. To determine whether these prostate cancer cell lines were also producing activin, LNCaP and PC-3 cells were treated with follistatin. Again, only the LNCaP cells responded, with growth acceleration noted by 24 h. As PC-3 cell responses to activin could be independent of cell proliferation, we transfected LNCaP and PC-3 cells with a known activin- responsive promoter/reporter gene construct (p3TP-Lux) and treated cells with activin. Only LNCaP cells produced a measurable response in luciferase activity. Finally, we attempted to determine whether the PC- 3 cell resistance to activin was mediated via a transferable factor. PC- 3 conditioned medium was added to LNCaP cells in the absence or presence of exogenous activin and had a small, but statistically nonsignificant (P < 0.09), action to blunt the actions of activin. We conclude that activin is a potent growth inhibitor of LNCaP cell growth. Moreover, these cells also produce activin, suggesting that locally derived activin may play a role in regulating cell proliferation. Despite expressing messenger RNAs for activin receptors, PC-3 cells are resistant to activin, perhaps the result of the production of an activin-blocking factor or a defective activin response system. These cell lines will thus serve as useful models in which to further study the cellular basis of activin action.

This article has been cited by other articles:

				H. Zhang, J. S. Bailey, D. Coss, B. Lin, R. Tsutsumi, M. A. Lawson, P. L. Mellon, and N. J. G. Webster Activin Modulates the Transcriptional Response of LssT2 Cells to Gonadotropin-Releasing Hormone and Alters Cellular Proliferation Mol. Endocrinol., November 1, 2006; 20(11): 2909 - 2930. [Abstract] [Full Text] [PDF]

				G. Chen, M. Nomura, H. Morinaga, E. Matsubara, T. Okabe, K. Goto, T. Yanase, H. Zheng, J. Lu, and H. Nawata Modulation of Androgen Receptor Transactivation by FoxH1: A NEWLY IDENTIFIED ANDROGEN RECEPTOR COREPRESSOR J. Biol. Chem., October 28, 2005; 280(43): 36355 - 36363. [Abstract] [Full Text] [PDF]

				Y. Fujii, S. Kawakami, Y. Okada, Y. Kageyama, and K. Kihara Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E927 - E931. [Abstract] [Full Text] [PDF]

				J. L. Carey, L. M. Sasur, H. Kawakubo, V. Gupta, B. Christian, P. M. Bailey, and S. Maheswaran Mutually Antagonistic Effects of Androgen and Activin in the Regulation of Prostate Cancer Cell Growth Mol. Endocrinol., March 1, 2004; 18(3): 696 - 707. [Abstract] [Full Text] [PDF]

				S. L. Mellor, E. M. A. Ball, A. E. O'Connor, J.-F. Ethier, M. Cranfield, J. F. Schmitt, D. J. Phillips, N. P. Groome, and G. P. Risbridger Activin {beta}C-Subunit Heterodimers Provide a New Mechanism of Regulating Activin Levels in the Prostate Endocrinology, October 1, 2003; 144(10): 4410 - 4419. [Abstract] [Full Text] [PDF]

				Y.-G. Chen, H. M. Lui, S.-L. Lin, J. M. Lee, and S.-Y. Ying Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin Experimental Biology and Medicine, February 1, 2002; 227(2): 75 - 87. [Abstract] [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				S Wildi, J Kleeff, H Maruyama, C A Maurer, M W Buchler, and M Korc Overexpression of activin A in stage IV colorectal cancer Gut, September 1, 2001; 49(3): 409 - 417. [Abstract] [Full Text] [PDF]

				A. J. Duleba, T. Pehlivan, R. Carbone, and R. Z. Spaczynski Activin Stimulates Proliferation of Rat Ovarian Thecal-Interstitial Cells Biol Reprod, September 1, 2001; 65(3): 704 - 709. [Abstract] [Full Text] [PDF]

				S. L. Mellor, M. Cranfield, R. Ries, J. Pedersen, B. Cancilla, D. de Kretser, N. P. Groome, A. J. Mason, and G. P. Risbridger Localization of Activin {beta}A-, {beta}B-, and {beta}C-Subunits in Human Prostate and Evidence for Formation of New Activin Heterodimers of {beta}C-Subunit J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4851 - 4858. [Abstract] [Full Text]

				Y. Zhou, H. Sun, D. C. Danila, S. R. Johnson, D. P. Sigai, X. Zhang, and A. Klibanski Truncated Activin Type I Receptor Alk4 Isoforms Are Dominant Negative Receptors Inhibiting Activin Signaling Mol. Endocrinol., December 1, 2000; 14(12): 2066 - 2075. [Abstract] [Full Text]

				D. C. Danila, W. J. Inder, X. Zhang, J. M. Alexander, B. Swearingen, E. T. Hedley-Whyte, and A. Klibanski Activin Effects on Neoplastic Proliferation of Human Pituitary Tumors J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1009 - 1015. [Abstract] [Full Text]

				S. J. McPherson, S. L. Mellor, H. Wang, L. W. Evans, N. P. Groome, and G. P. Risbridger Expression of Activin A and Follistatin Core Proteins by Human Prostate Tumor Cell Lines Endocrinology, November 1, 1999; 140(11): 5303 - 5309. [Abstract] [Full Text]

				S. Zhang, M.-L. Hsieh, W. Zhu, G. G. Klee, D. J. Tindall, and C. Y. F. Young Interactive Effects of Triiodothyronine and Androgens on Prostate Cell Growth and Gene Expression Endocrinology, April 1, 1999; 140(4): 1665 - 1671. [Abstract] [Full Text]

				T. Z. Thomas, H. Wang, P. Niclasen, M. K. O'Bryan, L. W. Evans, N. P. Groome, J. Pedersen, and G. P. Risbridger Expression and Localization of Activin Subunits and Follistatins in Tissues from Men with High Grade Prostate Cancer J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3851 - 3858. [Abstract] [Full Text] [PDF]

				D. L. Segev, Y. Hoshiya, M. Hoshiya, T. T. Tran, J. L. Carey, A. E. Stephen, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo PNAS, January 8, 2002; 99(1): 239 - 244. [Abstract] [Full Text] [PDF]